Evidence map›Paper›PMID 34063247›Full record

ArticleViruses2021

Sheng-Teng Huang, Yeh Chen, Wei-Chao Chang, Hsiao-Fan Chen, Hsiang-Chun Lai, Yu-Chun Lin, Wei-Jan Wang, Yu-Chuan Wang, Chia-Shin Yang, Shao-Chun Wang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. A Tale of Two Proteases: MPharmaceuticals (Basel, Switzerland) · 2023
    Review
  10. Identification of Flavonoids fromMolecules (Basel, Switzerland) · 2023
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Prospects of Coffee Leaf against SARS-CoV-2 Infection.International journal of biological sciences · 2022
    Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sheng-Teng HuangSchool of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
Yeh ChenResearch Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan.
Wei-Chao ChangCenter for Molecular Medicine, China Medical University Hospital, Taichung 40402, Taiwan.
Hsiao-Fan ChenResearch Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan.
Hsiang-Chun LaiDepartment of Chinese Medicine, China Medical University Hospital, Taichung 40402, Taiwan.ORCID 0000-0001-7885-619X
Yu-Chun LinDepartment of Chinese Medicine, China Medical University Hospital, Taichung 40402, Taiwan.
Wei-Jan WangDepartment of Biological Science and Technology, China Medical University, Taichung 40402, Taiwan.
Yu-Chuan WangGraduate Institute of New Drug Development, China Medical University, Taichung 40402, Taiwan.
Chia-Shin YangGraduate Institute of New Drug Development, China Medical University, Taichung 40402, Taiwan.
Shao-Chun WangResearch Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0002-5477-1682
Mien-Chie HungResearch Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan.
China Medical University · TWAsia University · TW

Funding

China Medical University Hospital, Taiwan (DMR-109-199, DMR-110-004, DMR-110-009 and CRS-108-001 (S.-T.H))Chinese Medicine Research Center, China Medical University, under the Higher Education Sprout Project, Ministry of Education, Taiwan (CMRC-CHM-1 (S.-T.H))Ministry of Science and Technology of Taiwan (MOST 109-2327-B-039-003 (M.-C.H))
6 · The paper itself

Abstract

In late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic emerged to severely impact the global population, creating an unprecedented need for effective treatments. This study aims to investigate the potential of

Indexed as

COVID-19 Drug TreatmentAnimalsCell LineChlorocebus aethiopsCoronavirus 3C ProteasesCOVID-19HumansLungPandemicsPeptide HydrolasesPeptidyl-Dipeptidase APlant ExtractsProteolysisSARS-CoV-2ScutellariaSerine EndopeptidasesCoronavirus 3C ProteasesPeptide HydrolasesPeptidyl-Dipeptidase APlant ExtractsScutellaria barbata extractSerine EndopeptidasesSpike Glycoprotein, CoronavirusTMPRSS2 protein, humanpandemicScutellaria barbatasevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)viral pseudoparticles

Identifiers

PMID34063247
PMCPMC8147405
OpenAlexW3158942673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.